Mortality reduction benefits of a comprehensive cardiac care program for patients with occlusive coronary artery disease

Pharmacotherapy

Volumn 27, Issue 10, 2007, Pages 1370-1378

  Merenich, John A ^a,e,f   Olson, Kari L ^b,e   Delate, Thomas ^b   Rasmussen, Jon ^b,e   Helling, Dennis K ^c,e   Ward, David G ^d  

^a University of Colorado Health Sciences Center   (United States)

^b Pharmacy Department   (United States)

^c Pharmacy Operations and Therapeutics   (United States)

^d Kaiser Permanente Colorado   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f KAISER PERMANENTE   (United States)

Author keywords

Clinical outcomes; Comprehensive cardiac care; Coronary artery disease; Pharmacist; Risk reduction

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CORONARY ARTERY DISEASE; CORONARY STENT; FEMALE; HEALTH PROGRAM; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT OUTCOME;

AGED; ARTERIAL OCCLUSIVE DISEASES; BLOOD PRESSURE; CHOLESTEROL, LDL; COLORADO; COMPREHENSIVE HEALTH CARE; CORONARY ARTERY DISEASE; DATABASES, FACTUAL; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT DROPOUTS; PATIENTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEX FACTORS; STENTS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34948861188     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.10.1370     Document Type: Article

References (33)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
2. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
4. Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG. Angiotensin-Converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction. Arch Intern Med 2006;166:787-96.
5. Robinson JG, Maheshwari N. A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. Am J Cardiol 2005;95:373-8.
6. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419-25.
7. Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ 2005;330:1059-63. (Erratum in BMJ 2006;332:912.)
8. Danchin D, Cambou JP, Hanania G, et al. Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry. Am Heart J 2005;150:1147-53.
9. Lappe JM, Muhlestein JB, Lappe DL, et al. Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program. Ann Intern Med 2004;141:446-53.
10. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 2004;109:745-9.
11. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006;113:203-12.
12. LaBresh KA, Gliklich R, Liljestrand J, Peto R, Ellrodt AG. Using "get with the guidelines" to improve cardiovascular secondary prevention. Jt Comm J Qual Saf 2003;29:539-50.
13. Olson KL, Rasmussen J, Sandhoff BJ, Merenich JA. A global and sustained approach to lipid management of 8,014 patients with coronary artery disease: the 5-year Colorado Kaiser Permanente clinical pharmacy cardiac risk service (CPCRS) experience. Arch Intern Med 2005;165:49-54.
14. Spencer FA, Lessard D, Yarzebski J, Gore JM, Goldberg RJ. Decade-long change in the use of combination evidence-based medical therapy at discharge for patients surviving acute myocardial infarction. Am Heart J 2005;150:838-44.
15. Murchie P, Campbell NC, Ritchie LD, Simpson JA, Thain J. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. BMJ 2003;326:84-95.
16. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med 2005;143:659-72.
17. Merenich JA, Lousberg GT, Brennan SH, Calonge NB. Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience). Am J Cardiol 2000;85:A36-42.
18. Schwartz L, Adolf S, Clemetson D, et al. Initiating a tobacco cessation program during hospitalization for acute coronary events improves long term cessation rates [abstract]. Circulation 2002;106:abstract 19.
19. National Committee for Quality Assurance. Health plan employer data and information set (HEDIS)/NCQA quality compass 2005. Washington, DC: National Committee for Quality Assurance, 2005.
20. Helling DK, Nelson KM, Ramirez JE, Humphries TL. Kaiser Permanente Colorado region pharmacy department: innovative leader in pharmacy practice. J Am Pharm Assoc 2006;46:67-76.
21. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care 1995;33:783-95.
22. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
23. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244-8.
24. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 2005;21:485-8.
25. Crowley J, Hu M. Covariance analysis of heart transplant survival data. J Am Stat Assoc 1977;72:27-36.
26. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-8.
27. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-9.
28. Qureshi AI, Suri FK, Guterman LR, Hopkins N. Ineffective secondary prevention in survivors of cardiovascular events in the US population. Arch Intern Med 2001;161:1621-8.
29. Muhlestein JB. Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction. Drugs Aging 2004;21:583-95.
30. Harris ED, Record NB, Gipson GW, Pearson TA. Lipid-lowering in a multidisciplinary clinic compared with primary physician management. Am J Cardiol 1998;81:929-33.
31. Wilson TW, Quest DW, Wilson M, et al. A cardiovascular risk factor reduction clinic. Can J Cardiol 1999;15:887-981.
32. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of stain therapy in elderly patients. JAMA 2002;288:455-61.
33. Muhlestein JB, Horne BD, Bair TL, et al. Usefulness of inhospital statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001;87:257-61.